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COMMENT
PAST CULTURAL ACHIEVEMENT AS A
FUTURE TECHNOLOGICAL RESOURCE:
CONTRADICTIONS AND OPPORTUNITIES IN THE
INTELLECTUAL PROPERTY PROTECTION OF
CHINESE MEDICINE IN CHINA

Benjamin Liu*
I.

INTRODUCTION

The latter part of the 20th century has witnessed a renewed
interest in Chinese medicine (CM) both in China and abroad.'
What was once dismissed as superstition or the remnants of an
unenlightened China has suddenly become the key to providing
public healthcare in developing countries and a ray of hope in
developed countries. 2 At the same time, entrepreneurial individuals and organizations perceive CM as a moneymaking business
and fuel for technological development. The Chinese state views
its extensive experience with CM as representative of a competitive advantage in the post-WTO global economy. Therefore, it is3
actively promoting CM research, education, and investment.
One essential aspect of these activities is the protection of CM as
*

J.D. Candidate (2004) UCLA School of Law.

1. See Kelvin Chan & Jian-Qian Zou, The Way Forwardfor Chinese Medicine,
in THE WAY FORWARD FOR CHINESE MEDICINE 413 (Kelvin Chan & Henry Lee

eds., 2002).
2. See Kelvin Chan et al., The Progress of Chinese Medicine in Mainland
China, in THE WAY FORWARD FOR CHINESE MEDICINE, supra note 1, at 192; VOLKER SCHEID, CHINESE MEDICINE IN CONTEMPORARY CHINA: PLURALITY AND SYNTHESIS

34 (2002).

3. See Volker Scheid, Remodeling the Arsenal of Chinese Medicine: Shared
Pasts, Alternative Futures, in 583 ANNALS AM. ACAD. POL. & SOC. SCI. 137 (2002)

("The Chinese government has envisaged earnings from the sale of Chinese
medicines abroad in 2000 to exceed U.S. $80 million and is actively promoting a
strategy to increase these revenues in the future."); GAN ET AL., THE DEVELOPMENT
STRATEGY PLAN OF MODERNIZATION OF THE PRACTICE AND USE OF CMM (1998).
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a type of intellectual property under the Agreement on TradeRelated Aspects of Intellectual Property (TRIPS agreement).4
The TRIPS agreement and the propertization of knowledge
engendered bitter North-South divide. The Chinese genuinely
welcomed TRIPS in the area of CM because it can be used to
protect native interests and knowledge. Current discussions of
CM development regularly refer to the benefit of patent protection, and discussions of intellectual property rights (IPRs) in
China regularly legitimize the patent system through reference to
the development of CM. 5 At the same time, NGOs, conservationists, anthropologists, traditional communities, and some developing countries perceive inadequacies in the patent system. 6
They have urged the protection of traditional medicine under a
sui generis system created specifically for the protection of tradi7
tional knowledge (TK).
Critics of existing IPRs protection of traditional knowledge
highlight anecdotes of exploitive abuse. 8 However, these critiques rarely engage the social choices behind the doctrines. On
the other hand, in-depth analyses of the underlying policy considerations for patent and TK IPR systems do not mention the particular social context confronting CM in 21st century China. 9 This
paper attempts to bridge the gap by examining the economic and
informational interests underlying CM and IPRs protection. Section II provides background information on the practice of CM,
the current economic interest in CM, and the perceived goal of
protecting CM through an IPRs regime. Section III looks at the
theory underlying patent law and assesses the difficulties China
may encounter in realizing its CM aspirations through the patent
system. Section IV considers the theories underlying a sui
4. Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr.
15, 1994, VTO Agreement, Annex 1C, art. 31, in The Legal Texts: The Results of
the Uruguay Round of Multilateral Trade Negotiations 321, 334 (1999), 33 I.L.M. 81
[hereinafter TRIPS Agreement].
5. See, e.g., Chan & Zou, supra note 1, at 424.
6. For background information, see Ida Madieha Azmi, Intellectual Property
Aspects of Biological Resources-The Malaysian Perspective, in INTELLECTUAL PROPERTY ASPECTS OF ETHNOBIOLOGY 140-51 (Michael Blakeney ed., 1999); Ong Chui
Koon, IntellectualProperty Protectionof TraditionalMedicine and Treatments in Malaysia, in INTELLECTUAL PROPERTY ASPECTS OF ETHNOBIOLOGY, supra note 6, at
152-72.
7. See generally Koon, supra note 6, at 171; Uma Suthersanen, Legal and Economic Considerations of Bioprospecting,in INTELLECTUAL PROPERTY ASPECTS OF
ETHNOBIOLOGY, supra note 6, at 69.
8. See, e.g., Koon, supra note 6, at 171.
9. For examples of scholarship that examines IP policy in general, outside the
context of China, see WILLIAM KINGSTON, INNOVATION, CREATIVITY AND LAW
(1990) (discussing the relationships between information, market force, and IPR system); Suthersanen, supra note 7.
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generis alternative for the IPRs protection of TK and examines
its associated difficulties. Section V contrasts the difficulties of
protecting CM under the patent system and under a TK IPR system. Section VI concludes that a more satisfying answer is possi-

ble if China first prioritizes its interests and then infuses patent

protection with elements of TK IPRs.
Before proceeding with the substantive discussion, it is im-

portant to note the unique legal position CM occupies in the

IPRs scheme. The manufacture and sale of CM products necessarily calls forth considerations of trade secret law, unfair competition law, traditional trademark laws, and laws governing
geographical indications. 10 Within patent law and TK IPRs, CM
products trigger equally contentious moral questions regarding
the preservation of biodiversity and the patenting of living organisms. This comment eschews the complex interactions of these
issues and instead simply analyzes the effect of patent law and
TK IPRs on the information Common and resultant market competitiveness. Therefore the discussion is oversimplified, and its
final recommendations are qualified by these additional considerations. Although definitive answers must come from a more in
depth analysis of the national situations, this comment provides a

list of what China must consider in implementing IPRs that pro-

mote their CM aspirations while domesticating the TRIPS
agreement.
II. BACKGROUND
A.

DEFINITIONS

CM is the sum of healthcare practices in China since the beginning of Chinese history. 1 ' Attempts to define CM beyond the
10. Most importantly, the Regulations on Protection of Traditional Chinese
Medicines, Decree No. 106, ch. 2, arts. 6, 7 and ch. 3 (1992), provide a formalized set
of special trade secret protection for CM innovations with periods of protection varying according to the importance of the invention. However, the trade secret protection is fundamentally a mere elaboration of what the CM practitioners have been
doing (and sometimes quite successfully) for years-keeping the formulation to
themselves.
11. The use of herbal remedies and acupuncture in China began at least around
2800 B.C. For the next two thousand years physicians and pharmacists began formalizing and theorizing the practice of medicine. CM had spread to the neighboring
regions of Korea and Japan by the First Century. By 1 A.D., texts documenting
general medical theory, and information on specific diseases and treatment, as well
as medicinal substances and their methods of preparation, had all come into existence. These compilations were updated every dynasty, and the most well known
compendiums of pharmacopoeia, BEN CAO GANG MU [COMPENDIUM OF MATERIA
MEDICA] featured nearly 2000 substances encompassing plant, animal, and other
materials, and collected over 10,000 prescriptions. It was published in 1596 A.D.,
brought to Europe, and translated first into Latin, then into English, French, German, and Russian. During this period, European physicians also acquired acupunc-
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tautological invocation of China usually fall into two camps.

Within modern Chinese discourse, CM is a systematic practice of
distinguishing among various illness-causing imbalances of qi.
CM achieves health by restoring a patient's internal yin-yang

equilibrium via herbal remedies and physical manipulation. 12
Popular accounts interpret CM as a historically substantiated system of holistic medical interventions using natural products,
based on an intuitive understanding of the interaction between
the human body and the environment. 13 The terms "historical,"
"holistic," "natural," and "intuitive" are used dialectically to illustrate the difference between CM and the biomedicine prac-

ticed in the healthcare institutions of developed nations; the
latter is perceived to be "scientific," "reductionist," "synthetic,"

and "analytical." These sets of contrasting definitions risk constructing an imaginary CM practice-the former fantasizes a
non-existent coherence, and the latter polemicizes a non-existent
dichotomy. Any concrete definition of CM needlessly risks
marginalizing specific practices due to its inherent pluralism and
syncretism. 14 As I will discuss later, the inability to define CM
has ramifications for the IP protection of CM.
B.

THE ECONOMIC IMPORTANCE OF CHINESE MEDICINE

Chinese herbal preparations alone account for thirty to fifty
percent of all medical intervention in China, and CM delivers
healthcare to over twenty percent of the world's population. 15 In
ture via Dutch trade with Japan. The development of CM throughout this history
was uneven, with stagnation accompanying those eras in which patients turned to
the supernatural for help. However it was not until the introduction of Western
medicine in the 19th and 20th centuries that CM faced its greatest challenge. With
the demise of the Chin dynasty in 1911, the new Republic of China discouraged the
practice of CM as part of a program to modernize itself through adopting Western
technologies. The trend reversed when the Chinese Communist party came to
power and CM was integrated into the state healthcare system. Since the 1980s, the
Chinese government has been actively promoting the documentation, research, and
business of CM. See Kelvin Chan, The HistoricalEvolution of Chinese Medicine and
Orthodox Medicine in China, in THE WAY FORWARD FOR CHINESE MEDICINE,

supra note 2, at 8-20.
12. See Zhan-wen Liu, PhilosophicalAspects of Chinese Medicine from a Chinese Medicine Academician, in THE WAY FORWARD FOR CHINESE MEDICINE, supra

note 2, at 23-31 [hereinafter Chan, The HistoricalEvolution of Chinese Medicine].
13. For example, a physician of CM may examine the tongue color and read the
pulse profile of a patient reporting for arthritic pains and interpret the symptoms as
a case of "obstruction" type symptoms resulting from the depletion of qi and blood.
The prescription could include a complex formula containing over ten herbs or even
poisonous inorganic elements of sulfur in order to replenish the yang qi, cool and
strengthen the blood qi, and pacify the liver wood element.
14. See generally SCHEID, supra note 2.
15. See World Health Organization, TraditionalMedicine, Fact Sheet No. 134, at
http://www.who.int/health-topics/traditionalmedicine/en/ (last visited Dec. 30,
2002).
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addition, modified forms of CM are well established in Korea,
Japan, Malaysia, and other neighboring countries. CM has also
emerged as a major alternative to biomedicine in developed
countries. For example, acupuncture institutions have been set
up in all developed nations including Australia, Great Britain,
and the United States to deliver healthcare alternatives to or
complementary with standard biomedicines.1 6 The World Health
Organization (WHO) has set up the International Acupuncture
Training Center and the International Society of Acupuncture
China to train overseas physicians and to reand Moxibustion in 17
search acupuncture.
The demand for herbal health products and functional food
expands the impact of CM knowledge beyond the economics of
healthcare. By some estimates, the global sale of herbal products
is now a 25 billion dollar international business and increasing,
although only 3% of the trade originates from China. 18 CM-related trade includes ingredients and components of CM, manufactured CM formulations, CM supplies and equipments, and
functional food items.
The interplay between the pharmaceutical industry and CM
further increases the economic importance of CM. It is believed
that at least 25% of all prescription drugs have their origin in
plant chemicals and 75% of these were found by examining the
use of these plants in indigenous communities. 19 Knowledge of
the therapeutic effects of plants and animals has consistently provided biomedical researchers with directions for drug development, especially for illnesses for which there is currently no
satisfactory treatment. For example, herbs identified in CM have
been explored extensively for the treatment of cancer. 20 Two developments in the functioning and aim of the pharmaceutical industry will further elevate the role of CM in modern biomedical
research. First, instead of developing compounds to alter the biochemistry of specific diseases, the modern drug discovery effort
focuses on developing biologically active chemical "libraries"
containing millions of molecules and studying these libraries via
16. See Christoph Kunkel et al., The Progress of Chinese Medicine in Some
Countries in Europe: Belgium, Germany & Holland, in THE WAY FORWARD FOR
CHINESE MEDICINE, supra note 2, at 240-53.
17. Chan, The HistoricalEvolution of Chinese Medicine, supra note 11, at 18-19.
18. See Teresa Schroeder, Comment, Chinese Regulation of TraditionalChinese
Medicine in the Modern World: Can the Chinese Effectively Profit From One of Their
Most Valuable Cultural Resources?, 11 PAC. RIM L. & POL'Y J. 687, 688 (2002).
19. World Resource Institute, A Short List of Plant-BasedMedicinal Drugs, at
http://www.wri.org/wri/biodiv/pharmacy.htmI (last visited Jan. 6, 2002).
20. Jennifer Man-Fan Wan, The Progressof Using Chinese Herbal Medicines in
Cancer Research, in THE WAY FORWARD FOR CHINESE MEDICINE, supra note 2, at
136-37.
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the High Throughput Screening technology. Under the new paradigm, any technique capable of enriching the biological activity

of the chemical libraries can increase the hit rates of the screening process and the number of potential drug leads. A library
created from plant materials listed in the Materia Medica of CM
is thus a very powerful library for drug screening. Second, current medical challenges in developed nations often involve degenerative or chronic diseases featuring complex environmental
interactions, long epidemiological histories, and, slow onset of
symptoms. CM boasts the ability to modify and boost the body
to overcome or mitigate chronic diseases without the need to delineate the complex underlying biochemical process. These two
developments link historical CM knowledge with the contempo-

rary drug discovery process. 21 Incidentally, pharmaceutical companies in developing nations have been accused of engaging in
biopiracy, or the practice of collecting biological samples and local medical knowledge from communities within developing na-

tions without remuneration. 22

In addition to generating valuable goods and services, CM is

also a competitive tool accompanying China's entry into the
global market. In contrast with its belated development in key
technological areas such as medicinal chemistry, bioengineering,

and telecommunication, China possesses the most advanced CM
knowledge. The advantage in this area may spearhead China's
entry into the lucrative field of pharmaceuticals. Apart from its
economic importance, CM embodies national history and cul-

tural heritage. Therefore the Chinese government and con21. For the effort of combining the above mentioned effort, see Beijing Genomic Institute, BGI Super Computer Center: Platforms,at http://coe.genomics.org.cn/
platform.htm (last visited Jan. 6, 2002) ("HTS has been well developed recently and
widely used by all pharmaceutical companies in the world for discovery of new drug
lead compounds. The traditional Chinese herbal medicine offers the rich source for
nature compounds, which may have higher hits rate for HTS. The goal of applying
HTS in Chinese herbal medicine is try to develop more new effective drugs from
TCM. The [targets] are related with obesity, inflammation, cancer, asthma, and cardiovascular diseases.").
22. See Lakshmi Sarma, Note, Biopiracy: Twentieth Century Imperialism in the
Form of InternationalAgreements, 13 TEMP. INT'L & COMP. L.J. 107 (1999); Ketih

Aoki, Neocolonialism, Anticommons Property,and Biopiracy in the (Not-So-Brave)
New World Order of InternationalIntellectual Property Protection, 6 IND. J. GLOBAL
LEGAL STUD. 11 (1998). A famous example is the turmeric patents, where a plant
known for its wound-healing properties in India was patented for the same utility by
an American in United States. See David Downes, How Intellectual Property Could
be a Tool to Protect Traditional Knowledge, 25 COLUM. J. ENVTL. L. 253, 278-79
(2000). In an analogous vein, a U.S. seed firm has brought seed from Mexico, patented the Enola beans with a yellow hue in U.S., enforced this patent against all
beans imported from Mexico with a yellow hue, and levied a 6% royalty on the
imported beans. See Gillian Rattray, The Enola Bean Patent Controversy: Biopiracy,
Novelty and Fish-and-Chips,2002 DuKE L. & TECH. REV. 8 (2002).

HeinOnline -- 21 UCLA Pac. Basin L.J. 80 2003

2003]

PAST CULTURAL ACHIEVEMENT

cerned citizens view the unacknowledged and uncompensated

use of CM by foreign companies as an abuse or misuse of cultural
relics and a violation of national identity. 23 The State Administration of Traditional Chinese Medicine under the Ministry of
Public Health is now the central administrative body that overof CM and issues regulations governing the
sees the development
24
practice of CM.
C.

JUSTIFICATION FOR THE CREATION OF
CHINESE MEDICINE.

IPR FOR

Given the multitudinous economic benefits, it is no surprise
that discussions of CM increasingly drawn on IPRs. CM supporters believe that a systematic grant of IPR to CM knowledge and

products can incentivize investment in CM products and an ex-

pansion of the CM knowledge base. 2 5 From the healthcare per-

spective,

CM

remains

the

most

prominent

alternative/

complementary medicine in developed nations, and IPR can
channel resources to validate the use of CM in order to preserve
patient choice and diversify the medical repertoire. It is analogous to the support pharmaceutical and biotech industries in developed countries have shown for the expansion of IPRs to

include their efforts to convert natural preparations into orthodox treatment. The Chinese government, ever conscious of its
23. For discourse on China's CM aspiration, see generally Schroeder, supra note
18.
24. Id. at 702. Schroeder listed some of the prominent regulations: "Law on
Drug Management 1985; Law on Certified Physicians 1998; Regulations on the Protection of Wild Medicinal Resource; Regulations on the Protection of TCVM Drug
Varieties; Regulations on the Management of Medical Institutions; The Regulation
of Anhui Province on the Development of Traditional Chinese Medicine (2001); The
Regulation of Beijing Municipality on the Development of Traditional Chinese
Medicine (June 22, 2001); The Notice of the Ministry of Health Concerning Restriction the Production of Health Foods Using Licorice Root; Chinese Ehedra; Desert
Cistanche; Snow Lotus and Their Product in Raw Materials (June 1, 2001); The Regulations of Shanzi Province on the Development of Traditional Chinese Medicine
(May 21, 2001); The Measures of Tianjin Municipality for Administration of Chinese
Traditional Medicine Pieces for Decoration (Apr. 30, 2001); The Regulations of the
Inner Mongolia Autonomous Region on Traditional Mongolian Medicine and Traditional Chinese Medicine (Feb. 12, 2001); The Regulations of Gansuu Province on
Developing Traditional Chinese Medicine (Nov. 27, 2000 & Dec. 2, 2000); The Regulations of Jiangxi Province on the Development of Traditional Chinese Medicine
(June 27, 2000) (www.chinalegalchange.com); Circular of State Administration of
Chinese Traditional Medicine Ministry of Foreign Trade and Economic Cooperation
State Administration of Import and Export Commodity Inspection and Customs
General A Administration on Implementing the Quality Registration; Inspection
and Releasing System of Chinese Traditional Medicines to be Exported."
25. Id. at 715-16 ("Better protection for patentees will not only reward Chinese
creation of [Traditional CM] products, it will also encourage foreign investment.
Enforcing patent rights could also encourage standardization in the final
products.").
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new global role under the WTO membership, believes that IPRs
can transform CM into one of China's primary assets in the
global competition for technology and market share. The development of CM under an IPR system also fosters the use and
awareness of the budding IPR in China. 2 6 The goals of IPRs include the maintenance and preservation of Chinese cultural heritage. An IPR system would also provide China with the ability
to exclude others from the unauthorized use of CM product, and
processes, thereby stemming the tide of biopiracy within its
27
borders.
Proposals to propertize CM knowledge trace either the patent paradigm or the traditional knowledge paradigm. The Chinese government currently employs the patent system to protect
CM. 28 While the patent paradigm enjoys the convenience of an
established legal framework and international recognition, it is
only applicable to a fragment of total CM knowledge.2 9 In contrast, a sui generis system to propertize traditional knowledge can
be tailored to cover a significant portion of the total CM knowledge. However, such protection remains largely theoretical because the practical uncertainty of adopting an unprecedented
system cast doubts on its feasibility. Many scholars and advocates of developing nations continue to urge the WTO to adopt
traditional knowledge IPRs into the TRIPS agreement. 30 Therefore, an analysis of IPRs for CM must consider the strengths and
weaknesses of both the patent approach and the traditional
medicine approach, beginning with their rationales and methods
of operation.

26. For discussions on the role IPRs play in the development of CM, see Jing
Hong, Zhongyao Zhishi Caichan Quan Baohu de Duice [An Intellectual Property
Rights Response of Chinese Medicine], 1 WORLD SCIENCE & TECHNOLOGY-MODERNIZATION OF TRADITIONAL CHINESE MEDICINE 32 (1999).
27. Of course, China cannot change through domestic laws the U.S. patent law
that enables the pirates to patent the misappropriated information or plant in the
U.S. Although the U.S. should examine patent applications more carefully and
change its patent law to better reflect the role of TK as prior art that destroys patentability, the scope of the international dialogue is beyond the scope of this paper.
28. The Traditional Chinese Medicine Patent Database contains a collection of
CM related patents. Traditional Chinese Medicine Patent Database, at http://
tcm.patent.com.cn/englishversion/.
29. For Brazil's suggestion of a sui generis system of protection, see World Trade
Organization, Review of Article 27.3(b)-Communicationfrom Brazil, IP/C/W/228,
at 36 (Nov. 24, 2000) ("Protection provided by the conventional IPR regime is limited ... by conceptual factors, since certain aspects of the knowledge produced in
most traditional communities are not necessarily within the scope of the TRIPS

Agreement.").
30. Id.
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III.
A.

PATENT AND CM

THE PATENT MODEL AND THE PROMOTION OF

PHARMACEUTICAL INNOVATION

Under neo-classical economy theory, the patent system promotes the effective allocation of resources to innovation and
avoids what G. Hardin describes as the tragedy of the Commons. 3 1 The tragedy is that under a system where individuals are
allowed to maximize their self-interest using a common resource
(such as herding on a common grass lot), rational actors would
expand their economic enterprise (by adding sheep to a herd)
until the continuous expansion exhausts the scarce but common
resource (the grass). The freedom to use the Common brings an
eventual downfall to all.
While the public use of information does not appear to engender the tragedy of the Common because information cannot
be depleted in the same sense that tangible resources are exhausted, beneficial inventive activities would be depleted if the
inventor could not recuperate the cost of the invention. This is
the mirror image of the tragedy, where economically unaccounted resources lead to over-consumption. With information,
the existence of economically unaccounted resources causes
under-production. But the result is the same whether it derives
from the overuse of the environmental Common or the underproduction of the information Common. The amount of total information wealth for the society is constrained. One redress is to
devote social resources to the preservation and expansion of the
information Common, as is done when the public channels funds
to individual researchers via universities and government. 32 The
alternative patent approach is to create a private economic incentive such as the power of monopoly to realize the value of the
new information in the inventor. 33 Both approaches essentially
require the market system to account for the use of a common
resource in order to avoid the tragedy of the Common.
Economic efficiency demands that the invention noticeably
enlarge the future information Common. However, even where
the patent monopoly is justified by benefit to the public, it alters
the competitive environment between market players. A secondary attribute of the patent approach is that the allocation of resources to preserve the information Common is built into the
market in the form of a monopoly. Because the winner takes the
entire market, the patent system allows nimble innovators to out31. See Garret Hardin, The Tragedy of the Commons, 162 SCIENCE 1243-48
(1968).
32. See Suthersanen, supra note 7, at 45.
33. KINGSTON, supra note 9, at 81.

HeinOnline -- 21 UCLA Pac. Basin L.J. 83 2003

PACIFIC BASIN LAW JOURNAL

[Vol. 21:75

compete established market actors but also allows established
companies to further consolidate their market power via research

and development efforts. 34 This is the distributive power of the
patent monopoly. A rational government, insofar as it has an
economic and political stake in the well-being of its industries,
has an economic and political stake in the intellectual effort it
chooses to propertize. It would attempt to control the distribu-

tive power and use the patent system to increase the market competitiveness of domestic companies vis-A-vis foreign producers.
Thus from the government's perspective, the most appropriate
patent system improves the competitiveness of national industry
in two ways-by enlarging the information wealth and by reserving legal monopolistic power for its own industries.
B.

CURRENT PROTECTION OF CM UNDER THE
PATENT SYSTEM

Under Article 27.1 of the TRIPS agreement, "[Platents shall
be available for any inventions, whether products or processes, in
all fields of technology, provided that they are new, involve an
inventive step and are capable of industrial application," where
"inventive step" and "capable of industrial application" could be
synonymous with "non-obvious" and "useful" respectively. 35 Because TRIPS does not define invention, and offers two versions

of the key terms, WTO member nations are free to create national patent systems that best promote their own interests.
However, the process of translating economic considerations into
a legal framework is not always easy.
Patent protections have been extended

pharmaceuticals.

to CM-based

Countries as diverse as China, Japan, the

United States, the United Kingdom, and Germany have issued
patents to CM practice, and products from acupuncture
processes to herbal mixtures. 36 There is a flurry of CM related
34. It has been argued that bigger enterprises have more funds for research and
development activities than will be available for smaller companies. However, the
bigger an enterprise is, the less receptive it is to new ideas and innovation. Consequently, there comes a point at which smaller firms can implement competitive innovations at a lower cost and counter balance the productive capacity and market
presence of the more established companies. Id. at 94.
35. TRIPS Agreement art. 27(1).
36. For a list of acupuncture patents in the U.S., see health.xq23.com, Acupuncture Resources, at http://www.health.xq23.com/pain/Acupuncture.html (last visited
Jan. 6, 2002). Specific examples of U.S. patents range from U.S. Patent 6,393,324, a
"method of blood pressure moderation," to U.S. Patent 6,421,560, a "device for
guiding spots for acupuncture and stimulation methods thereof." US Patent
6,468,541 details a hypoallergenic immune system stimulator and its powdered and
capsule form are comprised of four herbs based on CM, and US Patent 5,324,516
details a composition that is comprised of fructose and aqueous extracts of pueraria,
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patent activity in China, including the revealing in March 2002 of
the new Traditional Chinese Medicine Patent Database, which
contains all the 12,000 CM patent applications filed since the creation of the Chinese patent office in 1985. 37 A parallel database
collects CM information in order to prevent the patenting of previously known CM information.3 8 It was observed that the
Heilongjian Priovince Chinese Medicine Research Institute's unpatented herbal preparation Xiao Ke Chuang was widely copied
in China, but its later invention, Xuan Huang Lian, was a financial success because it was protected under a process patent.39
C.

PROBLEMS WITH THE PATENT PROTECTION OF

CM

Notwithstanding the ongoing CM patent issuance, the patent
system is poorly suited to the preservation and promotion of CM.
The theoretical scope of its protection is very limited because the
patent system only protects knowledge embodied in inventions.
Therefore, pure knowledge in the use of acupuncture points combinations or herbal mixtures is not patentable. Because the patent system protects inventions, the protectable CM product or
process is a tiny island in the vast sea of existing practice. To be
sure, the patent system would seem to offer some incentive to
embody CM in novel commercial products or to further CM research. It is generally agreed that the pharmaceutical industry
receives the most benefits under the patent system due to the
special strength of chemical patents and the difficulties for competitors to invent around the patents. 40 In addition, the patent
system has the benefit of reserving the wealth of CM knowledge
for the public rather than for specific stakeholders. However, the
patent system does not conserve CM qua CM. Patent holders
phaseoli radiati, and pinelliae tuber sufficient to reduce the effect of alcohol intoxication. Both patents referred to CM.
37. See Traditional Chinese Medicine Patent Database, supra note 28. The full
record is only available under the Chinese version.
38. The Traditional Chinese Medical Literature Analysis and Retrieval System
(TCMLARS) includes 73,275 references and abstracts to literature on acupuncture
and herbal medicines published since 1984. See http://wall.cintcm.ac.cn/webdkrhl/eindex.htm (last visited March 12, 2004).
39. Weibo Zhang, Lun Zhongyao Qiye Zhishi Chanquan de Baohu [On the Intellectual Property Protection of the Chinese Medicine Industry], 2 WORLD SCIENCE
TECHNOLOGY-MODERNIZATION
OF TRADITIONAL CHINESE MEDICINE 56
(1999), available at http://www.cintcm.com/lanmu/zhongyi-keyan/yanjiu-journal/
journal2/page56.htm#3 (last visited March 12, 2004).
40. KINGSTON, supra note 9, at 121. It was observed that in the West, chemical
patent law allows a patent to cover a molecule and all of the structurally analogous
molecules. Moreover, the therapeutic properties of chemicals are not well understood, and therefore it is difficult to replicate a therapeutic result of a patented molecule by uncovering a novel molecule. Recent discussions of CM patent suggest that
the same effect may be reproduced for herbal CM. See infra note 70.
&
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may choose to channel some profit back to the conservation and

development of CM-however, this is not built into the patent
system. If modern medicine, using patented pharmaceuticals de-

of business, it is
veloped from CM, drives practitioners of CM out
41
only the invisible hand of the market at work.
Even where the CM product or process is novel, it may fall
within specific legal exclusions. For example, the patent law in

many countries, including China, excludes "methods for the diagnosis or for the treatment of diseases. '4 2 This would seem to exclude any new techniques of acupuncture or diagnosis. 43 In
addition, the legal exclusion of a "product of nature" from patent
protection further complicates the patentability of herbal prepa-

rations. These exceptions have special public interest justifications that outweigh the social benefit of invention or the moral
right of inventorship. Unfortunately, they appear to exclude the
bulk of CM knowledge.
Due to these theoretical limitations and legal exclusions, the
patent system will not protect existing knowledge of and the

practice of CM because they are not novel.44 Nevertheless this is
not a "problem" per se if one is aware of the outcome and genuinely wishes to protect only those aspects of CM that are new.

For example, the patent system is adept at protecting the modern
pharmaceutical effort of distilling biological information and
41. Although one does speak of promoting and conserving basic research in
chemistry, biology, or electrical engineering via the patent system, the effect is not
inherent in the patent system, but rather, it is a developed manufacturing practice
that relies on chemistry, biology, and electrical engineering. When pharmaceutical
companies analyze pharmacologically active plants identified through CM, they are
using the CM knowledge in the context of biology or chemistry. In a parallel universe, where all pharmaceutics are herbal and the technological ability to manipulate plants exceeds the ability of organic synthesis, one can image the reverse
industrial effect, where patents would encourage companies to identify and cultivate
plants that contain a particular compound, instead of encouraging the identification
and synthesis of a molecule from the plant. Reality is necessarily a mixture of these
two modes of research, and the optimist can expect some level of conservation of
CM in China based on the native presence of CM.
42. Patent Law of the People's Republic of China, at http://www.sipo.gov.cn/
sipoEnglish/flfg.e/zlflfg__e/200203270002.htm.TRIPS (last visited March 12, 2004).
43. This is born out of practice. A search for acupuncture under the Chinese
patent database revealed only acupuncture devices but no method or process patent.
This is an irony considering that the U.S. grants method patent for acupuncture
under its patent law. See Tradition Chinese Medicine Patent Database, supra note
28 and accompanying text.
44. A search in the Traditional Chinese Medicine Patent Database for Chinese
medicine patent applications and an examination of the corresponding patent application (prosecution) history in the patent application database of the Chinese patent
office revealed that most CM applications fail to receive a patent. Some are dismissed with prejudice, some are abandoned during the application, and some failed
to meet the requirements for an examination on the merits. Therefore the sheer
number of CM patent applications masks the difficulties of obtaining a patent.
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chemical substances from CM knowledge. It is also consistent
with the national program of modernizing/westernizing CM in
China.
In practice, the patentability of a particular CM practice or
product is very hard to discern. No clear shore separates the isle
of invention from the sea of tradition. 45 The distinction between
medically useful patents and statutorily excluded medical treat-

ments seems to turn on semantics.46 Similarly, the difference between unpatentable "product[s] of nature" and patentable

derivatives is ambiguous. 47 The combination of a strong desire to

provide CM with patent protection, the narrow intersection between patent and CM, and the inherent uncertainty of the legal

45. The ability of the PuerariaeLobatae flower to alleviate hangovers was the
basis of a U.S. patent already discussed in note 36; however, it's illustrative of various difficulties in protecting CM in China. It had been known in China that the
PuerariaeLobatae flower is a cooling herb that down-regulates excessive heat. Its
sweet pungent classification targets the earth phase organ system of stomach and
pancreas. Therefore it is capable of alleviating feverish sensations and dryness of
mouth symptoms associated with excessive exogenous heat in the stomach system. It
is also known that intake of fermented drinks generates exogenous heat in the stomach system. It was not known until the introduction of biomedicine that ethanol
intoxication creates a feverish sensation and dryness of mouth. There are several
product patent claims based on this group of knowledge:
I. A product consists of the flower of PuerariaeLobatae useful for
reducing excessive exogenous heat in the stomach.
II. A product consists of the flower of PuerariaeLobatae useful for
reducing hang-overs from over consumption of fermented
beverages.
III. A product consists of the flower of PuerariaeLobatae useful for
reducing hang-overs from over consumption of alcohol.
IV. A product consists of the flower of Puerariae Lobatae useful for
alleviating ethanol intoxication.
I is not patentable because it is a known principle of CM. IV will be patentable if
"ethanol intoxication" is not the same as "excessive exogenous heat in the stomach."
Between I & IV are grades of "inventiveness" that depend purely on how a symptom is defined.
46. Statement IV from the previous footnote will not be excluded because the
patent is about a product, not a method. However, the claim stating that "[a]
method of treating ethanol intoxication consisting of eating the flower of Puerariae
Lobatae" is unpatentable because it is a method of treating a medical condition.
This highlights the subtle question of whether treating hang-overs is a medical intervention, which further turns on the question whether CM's concept of medical interventions is similar to other forms of medical intervention.
47. See JAYASHREE WATAL, INTELLECTUAL PROPERTY RIGHTS IN THE WTO
AND DEVELOPING COUNTRIES, 132-33 (2001). The examples in footnote 46 will fall
short of this criterion because all of the claims rely on the use of the flower. However, "the flower of PuerariaeLobatae" can be replaced with "a tea consisting of
warm water steeped with PuerariaeLobatae flower," "an aqueous extract of Puerariae Lobatae flower," "a powder of dried PuerariaeLobatae flower," and "an
eluted component of aqueous PuerariaeLobatae flower extract." A group of modified sugars in the PuerariaeLobatae flower was found to alleviate ethanol intoxication. So the phrase can be replaced with "a group of modified sugar extracted from
PuerariaeLobatae" or even "Isoflavonoids containing a carbon-carbon linked betaD-glucose moiety at the C-8 position," as was used in U.S. Patent 5,783,189.
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regime will lead to dubious patent grants, confused producers,
disappointing protection, and even mistrust of the patent system.
Although WTO member nations are required to promulgate
a patent system consistent with the TRIPS agreement, considera48
ble ambiguities exist within the language of the agreement.
Theoretically, each country can design a patent system that better suits its need, and it has been argued that the ambiguities of
the patent system give China substantial flexibility in fashioning
CM-friendly patent rules.49 It is possible to conceive changes that
will accomplish this goal. For example, China might remove the
exclusion of medical treatments or declare that useful plant and
animal extracts fall within the realm of inventions. Moreover,
the consistent application of a CM-friendly patent agenda over
time can clarify the ambiguous lines as the patent system
matures.
While the current ambiguity may indeed provide an opportunity for developing nations, one wonders if CM will be its most
direct beneficiary. The patent system both increases the amount
of overall informational resources and shifts the resource distribution among market players, but the patent system's maximization of one effect may compromise the other. A strict patent
system benefits those nations that already wield strong market
power and expertise in a given area, because industries within
their borders can invent ahead of the pack against foreign competitions, and there are fewer opportunities for the patent system
to redistribute their market power away to upstart companies
through a legal monopoly.50 Conversely, a relaxed patent system
has the reverse effect of benefiting nations that have a weaker
market power and expertise in an area. Budding industries
within the nations' borders can gain monopolies by inventing
even if the improvement ofnear or around existing technology,
51
fers less informational return.
48. Id. at 90.
49. Some attempts have been made regarding the patentability of one CM formulation that is the context of other existing formulations. See Yongfeng Zeng,
Zhongyao Zhuanli Shenqing de Xianzhuang Fenxi ii Shencha Biaozhun [A Current
Analysis and Examination Standard Regarding Chinese Medicine Patent Application], at http://www.bio-engine.com/garden/law/patent9.asp (last visited March 12,
2004).
50. A stringent patent system that rewards only inventive leaps, sparks of genius, and globally unknown discoveries will enlarge the information common to all,
but fewer industries can invoke the power of a legal monopoly grant to improve its
market position.
51. A more relaxed patent system that rewards incremental improvements, derivative effort, and local knowledge will generate greater distributive consequences,
but enlarge the information common to all at a higher overall cost to society.
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There already exists a tension between the desire to expand
CM information resources and to maintain the competitiveness
of the CM industry, where patent protection promoting one interest will generate less improvement of the other interest.
Moreover, the unique position of CM in China is that of one of
the few advanced disciplines in a technologically-lagging nation.
A relaxed patent system can promote growth in lagging industries. But it will also allow foreign competitors to enter the CM
markets and patent CM products in China against the native CM
industry. A stringent patent system may reserve monopolistic
power to Chinese institutions that are higher up on the CM food
chain and keep out foreign firms, but it will also keep the patent
system out of reach for domestic manufactures in the chemical
industry.
The current ambiguity masks subtle policy choices, and it is
not yet clear how patent law in China can promote underdeveloped industries while maintaining the CM lead. In order to maximize the competitive advantage, China needs a form of patent
protection that reflects the different conditions of CM and other
industries. This makes the design of its patent law more complicated than for a country that lags in every respect. The approach
must be facially neutral to survive the TRIPS requirement forbidding IP law from discriminating among industries. 52 A more
fundamental problem is that a stringent patent system can reserve competitive power onto Chinese CM industries and avoid
the problem of bio-piracy, but it further distances the patent system from the generous protection granted CM.
In summary, current patent law protects a small subset of
CM knowledge. Even within the realm of protection, CM inventions receive less protection than other articles or processes of
manufacture do because they are prone to fall within legal exceptions. The pressure to protect CM under ambiguous legal doctrines further plagues the quality of CM patents. Although
China retains some ability to shape its patent law and clarify legal
doctrines over time, it is not clear whether the eventual legal regime will promote CM given the competing interests within Chinese industries, between domestic and foreign pharmaceutical
firms, and between information Common and monopolistic
power.

52. TRIPS Agreement art. 27(1) ("[P]atents shall be available and patent rights
enjoyable without discrimination as to the place of invention, the field of technology
and whether products are imported or locally produced.").
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TRADITIONAL KNOWLEDGE PROTECTION
AND CM
THE TRADITIONAL KNOWLEDGE MODEL AND THE

COMPENSATION OF ETHNOBIOLOGICAL INFORMATION

Many scholars have argued that the current patent system
cannot protect TK for many of the same reasons discussed in the
previous section. 53 Ultimately, the patent system encourages new
invention, but a TK holder desires protection for his existing
ethnobiological knowledge. Justifications for bestowing a property right upon TK vary according to one's intellectual origin. A
professional model argues that communities rich in TK provide a
valuable service when they maintain, transmit, and disseminate
their expertise. Because their knowledge and service are economically important, the society should establish a mechanism to
recompense these communities. 54 A related equity consideration
is the general impoverishment and exploitation indigenous communities have suffered in recent history. In light of this history,
the external use of TK without compensation or even against the
native interest is another form of imperialism, especially when
TK is one of the remaining few resources indigenous communities possess.
As compelling as these arguments may be, a theory of justice and victimization is probably less relevant for WTO nations
than are arguments based on economic theory. Interestingly, the
argument justifying TK is closely related to the argument justifying the patent system. Currently TK is a type of informational
Common-it is a public good without an associated price tag. 55
The use of any specific piece of information does not exhaust the
appropriated information. However, a particular type of tragedy
associated with the TK Common is that over-exploitation of
traditional knowledge and its associated traditional culture will
"exhaust" the source of that information and potential for new
information. This is the economic euphemism for the demise of a
traditional culture and lifestyle. Once the people and lifestyle
disappear, the information Common containing the traditional
knowledge will be forever lost to humanity, not unlike the loss of
a plant species or the ozone layer. 56 The solution to this tragedy
53. See supra notes 7 and 8 and accompanying text.
54. Suthersanen, supra note 7, at 68-69.
55. Its value actually derives from its being a public commodity within the local
community but private with respect to the rest of the world. Thus, TK can approximate private property when viewed from a distance.
56. The destruction of knowledge is also inefficient. Once the community disappears, resources would have to be poured into recreating the same information,
just as cement had to be reinvented even though the Romans used it extensively
many centuries earlier. Even without the complete demise of the TK, biopiracy or
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is therefore the privatization of traditional knowledge and redi-

rection of economic resources into TK-rich communities.
B.

PROPOSED

TK

PROTECTION FOR TRADITIONAL MEDICINE

Currently TK is not protected under the TRIPS agreement.

However, it is recognized in the context of the United Nations
Convention on Biological Diversity (CBD). 57 A few countries
have implemented national laws granting special protections to
folklores, traditional designs, agricultural know-how, and
ethnobiological information. 58 Even those TK-rich countries that
did not create sui generis protection have also taken steps to

counter the (mis)appropriation of their TK wealth in the form of
preventing outsiders from receiving IPRs for products derived

patenting of TK by a known local group is also inefficient because the society is
granting the power of monopoly (losing the efficiency of a competitive market) without deriving a corresponding increase in knowledge (since the knowledge was already in existence). It would have been socially cheaper, instead of granting the
monopoly, to invest in the TK that possesses the knowledge in the form of TK IPRs
and ask the originator(s) to spread hisknowledge.
57. Article 8 of the CBD states:
Each Contracting Party shall, as far as possible and as appropriate:
(j) Subject to its national legislation, respect, preserve and maintain
knowledge, innovations and practices of indigenous and local communities embodying traditional lifestyles relevant for the conservation and sustainable use of biological diversity and promote their
wider application with the approval and involvement of the holders
of such knowledge, innovations and practices and encourage the
equitable sharing of the benefits arising from the utilization of such
knowledge, innovations and practices
Convention on Biological Diversity, available at http://www.biodiv.org/convention/
articles.asp?lg=0&a=cbd-08 (last visited March 12, 2004).
58. Panama promulgated Special Intellectual Property Regime Governing the
Collective Rights of Indigenous People, for the Protection and Defense of their Cultural Identity and their TraditionalKnowledge, and other Provisions, Law No. 20 of
June 26, 2000, which reserves collective indigenous rights for the indigenous community and excludes a third party from obtaining IPRs on creations derived from
knowledge and practices of the indigenous people. What is traditional is to be determined via a registration system via an application filed by the traditional society.
Moreover, the government is now devising a system that compensates the indigenous people for non-native uses of TK. The law of the Philippines is even more
explicit, granting an IPR in cultural integrity that allows an indigenous community to
issue licenses and permits to those wishing to enter the demarcated area or use TK
and collect fees for the license and royalties for research or publications using TK.
Brazil, Thailand, and the Organization of African Unity all promulgated their own
rules. See World Intellectual Property Organization, Questionnaires and Surveys:
Survey on Existing Forms of Intellectual Property Protectionfor TraditionalKnowledge, Intellectual Property and Genetic Resources, Traditional Knowledge, and
Folklore, at http://www.wipo.int/globalissues/questionnaires/index.html (last visited
March 12, 2004).
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from TK. 59 Finally, countries have used existing IPRs creatively
60
to protect some aspect of their TK.
One of the most contentious debates in the WTO is the appropriateness of requiring all member countries to adopt some
type of sui generis system of protection for TK: developing countries support its protection, and developed countries, especially
the United States, oppose its protection. Critics of a sui generis
protection argue that TK is indistinguishable from information,
methods, knowledge, and ideas that properly belong to the information Common. Privatization of well-known TK will increase
the cost of productive economic activities without generating a
corresponding increase in knowledge. In practice, traditional
communities may span a wide area, and TK may be spread
among several culture groups spanning different countries; consequently, the propertization of TK across geopolitical boundaries may pit the interest of one traditional community against
that of another in a complex political and diplomatic match. It
will also be difficult to assign the proper value to TK. All of
these factors add to the cost of implementing a system to distinguish protectable knowledge from public knowledge.
All of these arguments find counter-examples within existing IPRs. The objection that TK belongs to the information
Common is similar to the recent debate regarding the patentability of business methods such as reverse auctioning. In that case,
the argument did not stop the United States from granting IPR
protection to business methods. Privatization of well-known information may increase the cost of existing knowledge, but this
increase only reflects the social cost of heretofore unacknowledged or unrecompensed use of TK. The income will support the
TK conservation effort, not unlike the incorporation of sustainable development in environmentally responsible accounting practices. The difficulties of valuation are resolved in the patent
system by granting monopoly rights and allowing the market to
determine the value of the invention. There is no reason why the
protection of TK cannot follow a similar approach. Current proposals of a sui generis system include a government-sponsored
59. See generally Graham Dutfild, Protecting and Revitalizing TraditionalEcological Knowledge: Intellectual Property Rights and Community Knowledge
Databasesin India, in INTELLECTUAL PROPERTY ASPECTS OF ETHNOBIOLOGY, supra

note 6, at 100 (discussing India's effort in creating a public database of traditional
knowledge to counter foreign patents such as the turmeric patent that claims India
TK as a foreign invention).
60. Australia prevented the publication of a book containing information of sacred sites using the common law doctrine of confidential information in Foster v.
Mountford, 29 F.L.R. 233 (1976), and awarded collective royalty compensation for
imported carpets that were claimed to be the work of aborigine artists in Milpurrurru v. Indofurn Pty. Ltd., 30 I.P.R. 209 (1995).
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contractual system that allows traditional communities to trade
TK for payment from information users.6 1 Alternatively, a regulatory scheme may give TK holders the ability to grant a bioprospecting license for a fee. 62 Another proposal involves perpetual property rights to TK vested in the entire traditional community of a particular locale. 63 Whatever the result of the discussion
may be, developing countries will probably be free to implement
a TK-specific IPR regime because the TRIPS agreement guarantees the minimum IPRs a government must provide but does not
set a ceiling on IPRs. Therefore, national governments are free
to grant IPRs to TK.
C.

PROBLEMS WITH THE

TK

PROTECTION OF

CM

The World Health Organization refers to CM as a type of
tradition medicine, which it defines as "the sum total of the

knowledge, skills, and practices based on the theories, beliefs,
and experiences indigenous to different cultures, whether explicable or not, used in the maintenance of health as well as in the
prevention, diagnosis, improvement or treatment of physical and
mental illness."'64 Intuitively, CM appears to be a type of TK. In
light of the previously mentioned theoretical inadequacy of applying patent information to CM, TK IPRs appear to be an attractive alternative. Unlike the patent system, TK protection
covers the basic knowledge content of CM and preserves existing
information. Moreover, TK-specific IPRs can decouple the protection of CM from the promotion of other industries to avoid
the conflict of policy considerations between CM and other lagging industries. The TK framework will provide a more direct
tool to capture the value of useful CM knowledge and account
for externalities resulting from the unauthorized use of CM
knowledge through biopiracy or imitation.
However, the propertization of CM knowledge confronts all
the criticisms leveled at the propertization of TK in the worst
way. As mentioned earlier, CM is now a widespread phenomenon, and the unilateral propertization of CM knowledge in China
61. The Philippine system is an example. See Suthersanen, supra note 7, at 6869.
62. Id.
63. Gurdial Singh Nijar, In Defense of Local Community Knowledge and Biodiversity: A Conceptual Framework and the Essential Elements of a Rights Regime
(Third World Network ed., 1996), availableat http://www.mindfully.org/GE/Community-Knowledge-Biodiversity.htm (last visited March 12, 2004).
64. World Health Organization, General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine (2000), WHO/EDM/Traditional
Medicine/WHO/EDM/TRM/2000.1, available at http://www.who.int/medicines/library/trm/who-edm-trm-2000-1/who-edm-trm-2000-len.shtml (last visited Feb. 3,
2004).
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will surely raise objections from Japan, Korea, Malaysia, and
other nations whose medical practices share the CM knowledge
Common. The unilateral propertization of CM knowledge in
China will also have unpredictable effects on overseas CM practitioners and on China's agenda of promoting CM as the other
global healthcare system. The TK content of CM is not easily
defined. The CM rubric encompasses a pluralistic and syncretistic body of knowledge that radiates from healthcare outward to
the mundane and the philosophical, encompassing divergent concepts including yin-yang, tai-chi exercise, healthful diets, and anger management. The selection of what to include and what to
exclude will likely be an arbitrary task. Even within the narrow
healthcare or pharmaceutical sense (whatever that may be), it is
not clear where TK ends and public knowledge begins because
contemporary CM practice in China has been influenced by imported biomedicine and vice versa. Similarly, it is difficult to isolate the TK aspect in the numerous projects of modernizing CM
or to answer the metaphysical question of whether modernized
CM is still TK.65 It is also not clear who should be the owners of
the new IPRs though the membership of that group will certainly
be vast-whether it is the Chinese government, the practitioners
of CM, or the communities in which CM is the predominant form
of medical care. To further complicate matters, there are ethnic
minorities in China with distinct medical practices; it is not clear
66
if their TK should be considered CM.

65. This is merely the mirror image of the problems regarding prior art encountered during the discussion of patent. See supra notes 46-49. The situation described
in notes 46-49 can be extended in this section as well. For example, the statement
"the flower of PuerariaeLobatae is useful for reducing excessive exogenous heat in
the stomach" will probably satisfy the requirement of TK. However, it becomes
contentious and comes close to depleting the information common if the statement
"Isoflavonoids containing a carbon-carbon linked beta-D-glucose moiety at the C-8
position is useful for reducing excessive exogenous heat in the stomach" was treated
as TK.
66. For a general discussion of the state of ethnic medicine in China, see
Guoben Zhu, Zhongguo Minzu Yixue Shi Dangdai Weisheng Ziyuan de Zhongyao
Zucheng Bufen [Chinese Ethnic Medicine is An Important Partof the Contemporary
Medical Science], at http://www.cmam.org.cn/lm01/Im01.htm (last visited March 12,
2004). Chinese Medical Association of Minorities is an organization promoting the
study and use of ethnic medicine. According to the organizers: "Although ethnic
medicine could be understood as a homonym for traditional medicine, the phrase
'ethnic' is understood in China to mean 'ethnic minorities.' Thus 'ethnic medicine' is
the traditional medicine of the various ethnic minorities." Id. Within China, the
discussion of traditional medicine often implicates ethnic medicine as well. However, the distinction (or the lack of) between CM and ethnic medicine raises a local
identity issue and reenacts a local version (CM versus ethnic CM) of the global discursive battle between the dominant medical thoughts and alternative treatments
(Biomedicine versus CM). This is problematic enough when Tibet and Mongolian
medicines are included in Chinese medicine. It is even more problematic when Chinese ethnic medicine includes the practice of ethnic Thai or ethnic Korean Chinese.
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CM is TK that has transgressed its proper place. At one
time, it faced extinction under the onslaught of technological hegemony. Now it is a national industry merging with and transforming mainstream practices, and no longer in danger of
disappearing. In the same sense that alchemy is traditional
knowledge but chemistry is not, the practical incompatibilities
between CM and TK IPRs merely signal the gradual acceptance
of CM and the lessening need to ensure the survival of CM via

conservatory means. In this fundamental sense it fails the conservational model justifying TK IPRs.
Perhaps it is because of the awareness of these thorny issues
that the Chinese response to a sui generis TK protection of CM
has been muted. Countries such as Thailand or the Philippines

are aware that patent protection is inadequate for the protection
of their TK, and they are exploring the possibilities of TK IPRs.

In contrast, China has been actively promoting patent efforts in
the CM area and self-consciously excluding any proposal for TK
IPRs, despite the difficulties of protecting CM via the patent
system.67
V.

THE PARADOX OF CM

When the patent system is juxtaposed with TK IPRs, the difficulties of providing adequate protection to CM emerge as a set
of paradoxes. The first paradox of IPRs for CM is that CM is too
modern, advanced, widespread, international, civilized, and powerful to be considered a TK, but not so much so to utilize the

existing IPR system. This statement locates the misfit in the current state of CM in China. CM has multiple faces-it is a collec67. During the Inter-Regional Workshop on Intellectual Property Rights in the
Context of Traditional Medicine, the Chinese representative urged the protection of
TK through the incorporation of TK into the national healthcare system and the
establishment of a patent system that flexibly employs the terms "invention," "patentability," "exclusion from patent," "parallel trade," and "compulsory licensing,"
even though other nations clamored for a sui generis system. See generally World
Health Organization Geneva, Report of the Inter-Regional Workshop on Intellectual
Property Rights in the Context of Traditional Medicine, WHO/EDM/TRM/2001.1

(2000) (last modified Feb. 8, 2002). It is interesting that India, a nation that reacted
strongly against the foreign patenting of traditional plant medicine, also remains
watchful of a sui generis system. See World Trade Organization, Protection of Biodiversity and TraditionalKnowledge-The Indian Experience, WT/CTEIW/156,IP/
C/W/198, at 26 (2000) ("Some experts suggested that a sui generis system separate
from the existing IPR system should be designed to protect knowledge, innovations
and practices associated with biological resources. However, the parameters, elements and modalities of a sui generis system are still being worked out."). India is a
populous and heterogeneous country featuring several well-established traditional
medicines that are marching into the modern era. It and China face a dilemma that
cannot be solved by cordoning off a section of the population or knowledge and
declaring it traditional.
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tion of practices and beliefs regarding the truths about the world,
an interconnected body of manifested knowledge, or an adaptive
discipline capable of generating information and transformation.
Each one of these claims envisions different "needs." Neo-classical economic theory can tell us why one type of protection is better than the other, but the rational choice of whether a body of
knowledge requires patent protection (promotion) or TK protection (conservation) depends on the perceived character of the existing knowledge. The process of characterization of a body of
knowledge entails the endorsement of one set of characters to
the exclusion of another. Unfortunately, CM knowledge straddles the gulf, and any attempt to imbue CM with one set of characteristics excludes the other aspects of CM. This is why the
marriage between CM and patent is an unhappy one - the patent
system denies the unique history of CM and instead treats it as
ordinary food supplements or a subcategory of biomedicine.
Even more unfortunately, it is a forced marriage because refusal
to submit to either category would leave it with no IPR
68
protection.
The second paradox of IPRs for CM is that while IPRs purport to maintain or enlarge the information Common, the government that promotes IPRs wants to maintain or enlarge its
domestic industry. This is a statement about the stress of national IPRs in an international context. The current desire to
protect CM is an example of one's having his cake and eating it
too. Those who want to promote CM as an internationally recognized national (Chinese) treasure desire to erect a high wall
around CM to keep out trespassers. At the same time, they want
the wall to be flexible enough for easy expansion of the information territory. The agenda of the developed countries are no different-the U.S.'s vehemence in the promotion of TRIPS can
largely be explained by the benefit it would receive through domestic right holders in the entertainment, software, and pharmaceutical industries. But developed countries can have their cake
and eat it too because their industrial practice and technical expertise are locked in the same orthodoxy and institutions, with
enough market power and information resources beyond those
of developing countries to outstrip foreign upstarts from the domestic market. However, a developing country constantly faces
foreign competition within its territory.
The third paradox of IPRs for CM is that there is no IPR for
a tradition gone modern, an ethnobiology gone global, or a
marginalized art gone mainstream. This statement echoes the
68. It is also forced in the sense that developing nations, especially the United
States, have applied trade pressure to induce international recognition of IPRs.
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first paradox but locates the misfit in the IPRs regime. Prior to
the TK IPRs proposals, the dichotomy was drawn between an
economically significant inventions and economically neutral
knowledge Common. The erupting economical importance of
TK is now in the process of creating a new isle of protection out
of the economically invisible information sea. Developing countries and traditional societies, which up until now have had little
real estate on the isle of patent, are naturally drawn by the flowing milk and honey TK promises, especially when many have
seen their traditions as liabilities and not as assets. Necessary for
the struggle to form a new TK IPR is a set of jargons that set it
apart from existing IPRs. Consequently, the emergent TK contrasts with the traditional patent system and forms a new dialectical pair constructed alone: a hierarchical axis of modern versus
traditional. The patent system is justified in terms of expansion
and valorizes new developments over existing knowledge, while
the TK IPR system focuses on preservation and idealizes the culmination of the past. If a body of knowledge is in danger of disappearing, then TK IPRs are a reasonable form of protection. If
a body of knowledge is well established and awaits new development, then the patent system will provide better incentives. The
distinction may be clear, for example, between university biochemistry and local knowledge of plants. However, the story of
CM exposes the limit of imposing a power negotiated linguistic
construction of "invention" or "tradition" onto a body of knowledge that developed without characterizing itself as one or the
other.
VI.

CONCLUSION: FROM PARADOX TO SOLUTION

These paradoxes expose the deep tension between the desire
for IPR protection of CM protection and the limits of IPRs protection. However, this is not an effort to denounce all forms of
IP protection of CM, but rather an attempt to define the parameters of protection and the hard choices that must be made to
maximize the financial and informational benefit an IPR system
can generate. CM appears to fall through the crack between the
intersection of a TK IPR system and a patent system because it
possesses the character of both. The conceptual solution to this
difficulty is to visualize the intersection as an overlap, not a lacuna. The breakdown of the dichotomy between TK and patent
makes it possible to render the patent scheme more accessible to
CM by legitimizing the aspects of CM that are thought to be
traditional or old and by seeing advances not through the lens of
biomedicine, but CM. From an economic or informational perspective, there should be no reason to withhold inventions involving a "novel" combination of herbs or a "novel" use of
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acupuncture points. 69 Specific administrative rules developed

with the right priorities will lessen legal ambiguities surrounding
the coverage of new CM matters. 70 This is analogous to a recent

development in the United States whereby business methods and
computer software were incorporated into patent law and copyright law, respectively. 7 1 In order to reduce the conflicting inter-

ests mentioned earlier, decision-makers must articulate and
prioritize the values embodied in the currently monolithic desire
to protect CM. In the process China may have to accept foreign
CM patents as a necessary growing pain. Only with clear guidelines governing the reach of patent coverage and the level of inventiveness can China hope to maximize the sum of the CM
information Common and domestic industrial strength. Only
then can CM provide China with the competitive advantage72necessary to realize its economic aspirations under the WTO.
69. Some clarification is taking place. Recently, an article regarding the novelty
and inventiveness from the patent office clarified some of the legal ambiguities. The
current conception seems to be that an herb to a CM formulations as an atom to a
molecular medicine. Following the idea of chemical analogues, the recommendation
articulated the idea of an herbal analogue, where the use of an analogous herb that
leads to the ultimate function lacks inventiveness. However, the unexpected benefit
of replacing one herb for another will be deemed inventive. The recommendations
are made from a legal doctrine perspective, and not based on explicit discussions of
patent policy and national goals. The recommendations envision a fairly strict novelty requirement, which is beneficial for enlarging the information in the common
domain. However, it is contrary to the sentiment of offering extensive patent protection CM.
70. There is a Draft Regulation for Administering Chinese Medicine Patent, but
it focuses largely on the improvement of the CM prosecution capacity at the patent
office and regulations governing confidentiality and non-disclosure prior to the application of a CM patent. It limits what researchers may publish and collaborate
regarding a potentially patentable CM innovation. It also creates a national
clearinghouse system to monitor and process requests to publicize an innovation.
While the improvement of the patent processing capability will produce better patent grants, it is not clear whether the central information control function will serve
a useful purpose. In any event, it does not address the problems of ambiguities and
problematic legal exceptions. For the draft version of the regulation in Chinese, see
http://www.yaoxue.net/law/htm4/4-002.htm (last visited March 7, 2004).
71. Business methods, CM, and TK are similar in the sense that all three exhibit
more "ideas" then "embodiment" and are thought to be part of the intellectual
Common by many. That it was patentable suggests that China may similarly extend
its patent law to cover a bigger portion of CM, regardless of whether that is
desirable.
72. For an opinion discussing the difficulties of protecting CM under the existing regulatory regime, see Jinbiao Xia, Zhongyao Heshi Kangqi Zhishi Chanquan
Daqi? [When Can Chinese Medicine Carry the Banner of Intellectual Property?],
ZHONGGUO JINGJI SHIBAO [CHINA ECON. TIMES], Dec. 10, 2003, available at http:/

www.cet.com.cn/20031210/RESTATE/200312103.htm

(last visited March 12, 2004).

Xia, typical of CM advocates, provides specific solutions to shoehorn CM into ex-

isting IPR regime. This paper argues that the CM-centered approach should be replaced by an IPRs centered approach that locates the problem in the design of an
IPR regime.
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